8-K: Haemonetics to Acquire Attune Medical for $160 Million Upfront, Expanding Electrophysiology Portfolio

Haemonetics Corporation has announced a definitive agreement to acquire Attune Medical for $160 million in cash upfront, plus contingent payments, to expand its presence in the electrophysiology market.

Summary

• Haemonetics Corporation has agreed to acquire Attune Medical, a company that manufactures the ensoETM esophageal cooling device.
• The acquisition will cost Haemonetics $160 million in cash upfront, with additional payments contingent on sales growth and other milestones over the next three years.
• Haemonetics plans to fund the acquisition using a combination of existing cash and a draw from its revolving credit facility.
• The deal is expected to close in the first quarter of Haemonetics' fiscal year 2025, pending customary closing conditions.
• Attune Medical generated approximately $22 million in revenue in its most recent fiscal year, which ended December 31, 2023, more than doubling its revenue from the previous year.
• Haemonetics anticipates the acquisition will immediately boost revenue and earnings growth after the transaction is complete.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the strategic acquisition, expected revenue and earnings growth, and the potential for market expansion. The acquisition is presented as a positive step for Haemonetics.

Positives

• The acquisition will expand Haemonetics' presence in the electrophysiology market.
• The ensoETM device complements Haemonetics' existing vascular closure solutions.
• The ensoETM device reduces the likelihood of esophageal injury during cardiac ablation procedures.
• Studies have shown that the ensoETM device can reduce procedure times and patient readmissions, while increasing same-day discharge rates.
• The acquisition is expected to be immediately accretive to Haemonetics' revenue and earnings growth.
• Attune Medical's revenue more than doubled in the last fiscal year.

Negatives

• The acquisition will require Haemonetics to use a combination of cash and debt financing.
• The contingent payments are dependent on future sales growth and milestone achievements, which are not guaranteed.
• The transaction is subject to customary closing conditions, which could potentially delay or prevent the acquisition.

Risks

• The acquisition may not be completed in a timely manner or at all.
• Using debt to finance the acquisition will increase Haemonetics' indebtedness.
• The anticipated benefits of the acquisition may not be realized.
• There is a risk that Haemonetics may not be able to accurately predict the demand for Attune Medical's products.
• Competitive products and pricing could impact the success of the acquisition.
• Technical innovations could render the products obsolete.
• There are risks related to the use and protection of intellectual property.

Future Outlook

Haemonetics expects the acquisition to be immediately accretive to revenue and earnings growth following the completion of the transaction. The company also anticipates expanding the reach of the ensoETM device through its global channels.

Management Comments

• Stewart Strong, Haemonetics' President, Global Hospital, stated that Attune Medical's ensoETM will bolster Haemonetics' presence in the electrophysiology market and complement their leadership in Vascular Closure.
• Jay Istvan, Chief Executive Officer at Attune Medical, said they are thrilled to become part of Haemonetics and believe Haemonetics is the best company to bring ensoETM's benefits to more caregivers worldwide.

Industry Context

This acquisition reflects a trend in the medical device industry where larger companies acquire innovative technologies to expand their product portfolios and market reach. The focus on electrophysiology and interventional cardiology is a growing area within healthcare, driven by the increasing prevalence of conditions like atrial fibrillation.

Comparison to Industry Standards

• The acquisition of Attune Medical by Haemonetics is similar to other strategic acquisitions in the medical device sector, where companies seek to expand their product offerings and market share.
• For example, Medtronic's acquisition of Covidien aimed to broaden its portfolio and strengthen its position in various medical markets.
• Similarly, Boston Scientific has made several acquisitions to enhance its presence in specific therapeutic areas, such as electrophysiology.
• The $160 million upfront payment for Attune Medical, plus contingent consideration, is within the range of valuations seen in similar acquisitions of medical device companies with promising technologies and growth potential.
• Attune Medical's revenue growth of more than 100% year-over-year is a strong indicator of its market traction and potential, which aligns with the characteristics of companies that are often targeted for acquisition.

Stakeholder Impact

• Shareholders are likely to view the acquisition positively due to the expected revenue and earnings growth.
• Employees of both Haemonetics and Attune Medical may experience changes as the companies integrate.
• Customers of Haemonetics will have access to a broader range of products and solutions.
• Suppliers of both companies may see changes in their relationships.
• Creditors of Haemonetics may be impacted by the increased debt used to finance the acquisition.

Next Steps

• The transaction is expected to close in the first quarter of Haemonetics' fiscal year 2025, subject to customary closing conditions.
• Haemonetics will integrate Attune Medical's operations and products into its existing business.
• Haemonetics will work to expand the reach of the ensoETM device through its global channels.

Key Dates

Keywords

acquisition, Haemonetics, Attune Medical, ensoETM, electrophysiology, cardiac ablation, medical device, temperature regulation, healthcare, interventional technologies